[Outsourcing-Pharma] The pharmaceutical technology investment fund is partnering with and financing Atomwise, a company that provides AI solutions for drug discovery
[Drug Target Review] According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
[Crunchbase] Atomwise, which is using artificial intelligence for small molecule drug discovery, received a cash infusion of $123 million in an oversubscribed Series B financing.
[BioCentury] After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its
[VentureBeat] Atomwise, a startup using AI to accelerate drug discovery, today secured $123 million in funding. A spokesperson said the funds will enable the startup to scale its technology and team as it expands its portfolio of joint ventures with researchers at the University of Toronto, Duke University School of Medicine, Charles River, Bayer, Eli Lilly, […]
[San Francisco Business Times] As several companies emerge with the label of AI drug discovery, this San Francisco company has hundreds of projects and now a big funding round.